Enhanced Systemic Immune Reactivity to a Basal Cell Carcinoma Associated Antigen Following Photodynamic Therapy
- 1 July 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (13) , 4460-4466
Abstract
Purpose: Numerous preclinical studies have shown that local photodynamic therapy (PDT) of tumors enhances systemic antitumor immunity. However, other than single-case and anecdotal reports, this phenomenon has not been examined following clinical PDT. To determine whether PDT in a clinical setting enhances systemic recognition of tumor cells, we examined whether PDT of basal cell carcinoma resulted in an increased systemic immune response to Hip1, a tumor antigen associated with basal cell carcinoma. Experimental Design: Basal cell carcinoma lesions were either treated with PDT or surgically removed. Blood was collected from patients immediately before or 7 to 10 days following treatment. Peripheral blood leukocytes were isolated from HLA-A2–expressing patients and reactivity to a HLA-A2–restricted Hip1 peptide was measured by INF-γ ELISpot assay. Results: Immune recognition of Hip1 increased in patients whose basal cell carcinoma lesions were treated with PDT. This increase in reactivity was significantly greater than reactivity observed in patients whose lesions were surgically removed. Patients with superficial lesions exhibited greater enhancement of reactivity compared with patients with nodular lesions. Immune reactivity following PDT was inversely correlated with treatment area and light dose. Conclusions: These findings show for the first time that local tumor PDT can enhance systemic immune responses to tumors in patients, and validate previous preclinical findings.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Photodynamic Therapy Enhancement of Antitumor Immunity Is Regulated by NeutrophilsCancer Research, 2007
- CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cellsBritish Journal of Cancer, 2007
- Pharmacological Treatments for Basal Cell CarcinomaDrugs, 2007
- In situ photoimmunotherapy: a tumour-directed treatment for melanomaBritish Journal of Dermatology, 2006
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin®) for treatment of basal cell carcinomaLasers in Surgery and Medicine, 2006
- Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients With Non–Small-Cell Lung Cancer With Pleural SpreadJournal of Clinical Oncology, 2004
- Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of TumorsCancer Research, 2004
- Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipientsTransplantation, 2004
- Immunomodulatory aspects of photodynamic therapyExpert Opinion on Investigational Drugs, 1998